首页> 外文期刊>Clinical nuclear medicine >Spotlight on the Association of Radioactive Iodine Treatment With Cancer Mortality in Patients With Hyperthyroidism is Keeping the Highest Risk From Antithyroid Drugs in the Blind Spot
【24h】

Spotlight on the Association of Radioactive Iodine Treatment With Cancer Mortality in Patients With Hyperthyroidism is Keeping the Highest Risk From Antithyroid Drugs in the Blind Spot

机译:甲状腺功能亢进患者癌症死亡率的放射性碘治疗与癌症死亡率的聚光灯呈现出最高风险在盲斑的抗胆汁药物

获取原文
获取原文并翻译 | 示例
           

摘要

July 1, 2019, JAMA Internal Medicine released online an article authored by Kitahara et al entitled "Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism." The Altmetric Attention Score, a global indicator of interest from lay public and colleagues, skyrocketed to 223 by July 7, placing the article in the top 5% of all scored reports. The overall perception of death from cancer risk associated with I-131 is inflated and not supported by evidence. As co-authors of this article, we offer previously unpublished data and analysis that (1) disputes clinical significance of the associated risk from I-131 and (2) shows, again, that antithyroid drugs carry a statistically significant and a much more obvious cancer death risk.
机译:2019年7月1日,Jama内科在线发布了Kitahara等人题为“放射性碘治疗协会”患有甲状腺功能亢进患者的放射性碘治疗协会的文章。 矿产关注评分是一项全球兴趣指标,较为公共及同仁,飙升至7月7日,飙升至223,将文章放在所有被评分报告的前5%。 与I-131相关的癌症风险的总体对死亡的总体感知是膨胀的,并且证据不支持。 作为本文的共同作者,我们提供了以前未发表的数据和分析,(1)争议来自I-131和(2)的相关风险的临床意义再次表明,抗胆汁药物具有统计上显着和更明显的 癌症死亡风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号